

# FLUOCINOLONE ACETONIDE- fluocinolone acetonide oil

## Padagis Israel Pharmaceuticals Ltd

-----

### HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use **FLUOCINOLONE ACETONIDE TOPICAL OIL** safely and effectively. See full prescribing information for **FLUOCINOLONE ACETONIDE TOPICAL OIL**.

**FLUOCINOLONE ACETONIDE topical oil (scalp oil)**

Initial U.S. Approval: 1988

### INDICATIONS AND USAGE

Fluocinolone acetonide topical oil is a corticosteroid indicated for the treatment of psoriasis of the scalp in adults. (1)

### DOSAGE AND ADMINISTRATION

- Fluocinolone acetonide topical oil is not for oral, ophthalmic, or intravaginal use. (2)
- Do not use on face or intertriginous areas. (2)
- Apply a thin film of fluocinolone acetonide topical oil on the wet scalp, massage well and cover scalp with the supplied shower cap. Leave on overnight or for a minimum of 4 hours before washing off. (2)

### DOSAGE FORMS AND STRENGTHS

Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil) is a topical oil containing 0.01% fluocinolone acetonide, supplied in bottles containing 4 fluid ounces and with 2 shower caps. (3)

### CONTRAINDICATIONS

None. (4)

### WARNINGS AND PRECAUTIONS

- Endocrine System Adverse Reactions:
  - o Topical corticosteroids can produce reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria. (5.1)
  - o Systemic absorption may require evaluation for hypothalamic-pituitary-adrenal (HPA) axis suppression. Potent corticosteroids use on large areas, prolonged use or occlusive use, altered skin barrier, liver failure, and young age may increase systemic absorption. Modify use should HPA axis suppression develop. (5.1)
- Local Adverse Reactions: Local adverse reactions may include atrophy, striae irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis, and may be more likely with occlusive use or more potent corticosteroids. (5.2, 6.1)
- Ophthalmic Adverse Reactions: May increase the risks of glaucoma and posterior subcapsular cataract. Avoid contact of fluocinolone acetonide topical oil with eyes. Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation. (5.3)

### ADVERSE REACTIONS

The most common adverse reactions in pediatric subjects treated for atopic dermatitis ( $\geq 5\%$ ) were cough (20%), rhinorrhea (13%), pyrexia (10%), telangiectasia (7%), nasopharyngitis (7%), and hypopigmentation (7%). (6.1, 6.2)

**To report SUSPECTED ADVERSE REACTIONS, contact Padagis® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**See 17 for PATIENT COUNSELING INFORMATION.**

Revised: 7/2025

---

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### 1 INDICATIONS AND USAGE

**2 DOSAGE AND ADMINISTRATION****3 DOSAGE FORMS AND STRENGTHS****4 CONTRAINDICATIONS****5 WARNINGS AND PRECAUTIONS**

5.1 Endocrine System Adverse Reactions

5.2 Local Adverse Reactions

5.3 Ophthalmic Adverse Reactions

5.4 Allergic Contact Dermatitis

5.5 Concomitant Skin Infections

5.6 Use in Peanut-Sensitive Individuals

**6 ADVERSE REACTIONS**

6.1 Clinical Studies Experience

6.2 Postmarketing Experience

**8 USE IN SPECIFIC POPULATIONS**

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

**11 DESCRIPTION****12 CLINICAL PHARMACOLOGY**

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

**13 NONCLINICAL TOXICOLOGY**

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**14 CLINICAL STUDIES****16 HOW SUPPLIED/STORAGE AND HANDLING****17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

**FULL PRESCRIBING INFORMATION****1 INDICATIONS AND USAGE**

Fluocinolone acetonide topical oil is indicated for the treatment of psoriasis of the scalp in adults.

**2 DOSAGE AND ADMINISTRATION**

Fluocinolone acetonide topical oil is for topical use only. Not for oral, ophthalmic, or intravaginal use.

Wet or dampen hair and scalp thoroughly. Apply a thin film of fluocinolone acetonide topical oil on the scalp, massage well and cover scalp with the supplied shower cap. Leave on overnight or for a minimum of 4 hours then wash hair with regular shampoo and rinse thoroughly. Use daily as needed.

Discontinue fluocinolone acetonide topical oil when control of disease is achieved within 2

weeks, or contact the healthcare provider if no improvement is seen within 2 weeks.

Do not use fluocinolone acetonide topical oil on the face unless directed by the healthcare provider. Do not apply to intertriginous areas due to the increased risk of local adverse reactions [see *Adverse Reactions (6)*].

Do not apply to the diaper area; diapers or plastic pants may constitute occlusive use. [see *Warnings and Precautions (5.1)*]

### **3 DOSAGE FORMS AND STRENGTHS**

Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil) is a topical oil containing 0.01% fluocinolone acetonide, supplied in bottles containing 4 fluid ounces and with 2 shower caps.

### **4 CONTRAINDICATIONS**

None.

### **5 WARNINGS AND PRECAUTIONS**

#### **5.1 Endocrine System Adverse Reactions**

Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Cushing's syndrome, hyperglycemia, and glucosuria can result from systemic absorption of topical corticosteroids.

HPA axis suppression and Cushing's syndrome have been reported in patients receiving topical corticosteroids.

Conditions which increase systemic absorption include the use of more potent corticosteroids, use over large surface areas, use over prolonged periods, use of occlusive dressings, altered skin barrier, liver failure, and young age. Use of more than one corticosteroid-containing product at the same time may increase total systemic corticosteroid exposure. Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. The ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression.

If HPA axis suppression is documented, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids.

#### **5.2 Local Adverse Reactions**

Local adverse reactions may occur with use of topical corticosteroids, including fluocinolone acetonide topical oil, and may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Some local adverse reactions may be irreversible. Reactions may include atrophy, striae, telangiectasias, burning,

itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria [see *Adverse Reactions (6.1)*].

### **5.3 Ophthalmic Adverse Reactions**

Use of topical corticosteroids may increase the risks of glaucoma and posterior subcapsular cataract. Glaucoma and cataracts have been reported in postmarketing experience with the use of topical corticosteroid products. Avoid contact of fluocinolone acetonide topical oil with eyes. Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation.

### **5.4 Allergic Contact Dermatitis**

Use of topical corticosteroids can cause allergic contact dermatitis. Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing.

### **5.5 Concomitant Skin Infections**

Use of topical corticosteroids may delay healing or worsen concomitant skin infections. Treat concomitant skin infections with an appropriate antimicrobial agent. If the infection persists unchanged, discontinue fluocinolone acetonide topical oil until the infection has been adequately treated.

### **5.6 Use in Peanut-Sensitive Individuals**

Use caution in prescribing fluocinolone acetonide topical oil for peanut-sensitive individuals [see *Description (11)*].

Should signs of hypersensitivity present (wheal and flare reactions, pruritus, or other manifestations), or should disease exacerbations occur, discontinue fluocinolone acetonide topical oil immediately and institute appropriate therapy.

## **6 ADVERSE REACTIONS**

The following serious adverse reactions are discussed in more detail in other sections of the labeling:

- Endocrine System Adverse Reactions [see *Warnings and Precautions (5.1)*]
- Local Adverse Reactions [see *Warnings and Precautions (5.2)*]
- Ophthalmic Adverse Reactions [see *Warnings and Precautions (5.3)*]

### **6.1 Clinical Studies Experience**

Because clinical trials are conducted under widely varying condition, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

An open-label safety study was conducted in 29 pediatric subjects 3 months to 2 years old to assess the HPA axis by ACTH stimulation testing following use of the formulation of fluocinolone acetonide topical oil twice daily for 4 weeks. Fluocinolone acetonide

topical oil is not approved for use in pediatric patients for the treatment of psoriasis of the scalp. The most common adverse reactions were reported in the study:

**Table 1: Adverse Reactions in  $\geq$  2% Pediatric Subjects 3 Months to 2 Years of Age Treated with the Formulation of Fluocinolone Acetonide Topical Oil (Scalp Oil), N=30\***

<b>Adverse Reaction</b>	<b>n (%)</b>
Cough	6 (20)
Rhinorrhea	4 (13)
Pyrexia	3 (10)
Nasopharyngitis	2 (7)
Hypopigmentation	2 (7)
Abscess	1 (3)
Atopic Dermatitis	1 (3)
Eczema	1 (3)
Hyperpigmentation	1 (3)
Molluscum	1 (3)
Rash	1 (3)
Diarrhea	1 (3)
Otitis Media	1 (3)
URI	1 (3)
Vomiting	1 (3)

\* Includes one subject who withdrew at Week 2

## 6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of products containing topical corticosteroids. Because postmarketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- *Endocrine Disorders:* HPA axis suppression and Cushing's syndrome
- *Eye Disorders:* glaucoma and cataracts
- *Nervous System Disorders:* intracranial hypertension including bulging fontanelles, headaches, and bilateral papilledema

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

#### Risk Summary

Available data from case reports, case series, and observational studies on fluocinolone acetonide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Observational studies suggest maternal use of high to super-high potency topical steroids may be associated with an increased risk of low birthweight infants. Advise pregnant women to use fluocinolone acetonide topical oil on the smallest area of skin and for the shortest duration possible.

Corticosteroids can cause fetal malformations in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids cause fetal malformations after dermal application in laboratory animals.

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

### 8.2 Lactation

#### Risk Summary

There is no information regarding the presence of fluocinolone acetonide in breast milk or its effects on the breastfed infant or on milk production. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. To minimize potential exposure to the breastfed infant via breast milk, use fluocinolone acetonide topical oil on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply fluocinolone acetonide topical oil directly to the nipple and areola to avoid direct infant exposure [see *Warnings and Precautions (5.1)*]. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for fluocinolone acetonide topical oil and any potential adverse

effects on the breastfed infant from fluocinolone acetonide topical oil or from the underlying maternal condition.

## 8.4 Pediatric Use

The safety and effectiveness of fluocinolone acetonide topical oil have not been established in pediatric patients with psoriasis of the scalp.


### Evaluation in Peanut-Sensitive Pediatric Patients

A clinical trial was conducted to assess the safety of the formulation of fluocinolone acetonide topical oil which contains refined peanut oil, in patients with known peanut allergies. The trial enrolled 13 pediatric subjects with atopic dermatitis, 6 to 17 years of age. Fluocinolone acetonide topical oil (scalp oil) is not approved for the treatment of atopic dermatitis.

Of the 13 subjects, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The trial evaluated the subjects' responses to both prick test and patch test utilizing refined peanut oil, the formulation of fluocinolone acetonide topical oil and histamine/saline controls. Subjects were also treated with the formulation of fluocinolone acetonide topical oil twice daily for 7 days. Prick test and patch test results for all 13 subjects were negative to the formulation of fluocinolone acetonide topical oil and the refined peanut oil. One of the 9 peanut-sensitive subjects experienced an exacerbation of atopic dermatitis after 5 days of use on the formulation of fluocinolone acetonide topical oil.

## 11 DESCRIPTION

Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil) contains fluocinolone acetonide [(6 $\alpha$ , 11 $\beta$ , 16 $\alpha$ )-6,9-difluoro-11, 21-dihydroxy-16,17[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione, cyclic 16,17 acetal with acetone], a synthetic corticosteroid for topical dermatologic use. Chemically, fluocinolone acetonide is C<sub>24</sub>H<sub>30</sub>F<sub>2</sub>O<sub>6</sub>. It has the following structural formula:



Fluocinolone acetonide has a molecular weight of 452.50. It is a white crystalline powder that is odorless, stable in light, and melts at 270°C with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water.

Each gram of Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil) contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils, which contains isopropyl alcohol, isopropyl myristate, light mineral oil, oleth-2 and refined peanut oil.

Each packaged product contains 2 shower caps. The shower cap is made of low density polyethylene material with rubber elastic.

Fluocinolone acetonide topical oil is formulated with 48% refined peanut oil. The bulk refined peanut oil, used in fluocinolone acetonide topical oil is heated just below 232°C (450°F) for at least 15 minutes.

## **12 CLINICAL PHARMACOLOGY**

### **12.1 Mechanism of Action**

Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in psoriasis of the scalp is unknown.

### **12.2 Pharmacodynamics**

#### Vasoconstrictor Assay

Fluocinolone acetonide topical oil is in the low to medium range of potency as compared with other topical corticosteroids in vasoconstrictor studies. However, similar blanching scores do not necessarily imply therapeutic equivalence.

#### Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression

HPA axis suppression following administration of fluocinolone acetonide topical oil was not assessed.

### **12.3 Pharmacokinetics**

Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the product formulation and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may increase percutaneous absorption. The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids may be necessary due to the fact that circulating levels are often below the level of detection. Once absorbed through the skin, topical corticosteroids are metabolized, primarily in the liver, and are then excreted by the kidneys. Some corticosteroids and their metabolites are also excreted in the bile.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

No carcinogenicity, genotoxicity, or fertility studies were conducted with fluocinolone acetonide topical oil. However, some corticosteroids are genotoxic in various genotoxicity tests (i.e., the *in vitro* human peripheral blood lymphocyte chromosome aberration assay with metabolic activation, the *in vivo* mouse bone marrow micronucleus assay, the Chinese hamster micronucleus test, and the *in vitro* mouse lymphoma gene mutation assay).

## **14 CLINICAL STUDIES**

In a vehicle-controlled study for the treatment of psoriasis of the scalp in adults, after 21 days of treatment, 60% of patients on active treatment and 21% of patients on the drug vehicle had excellent to cleared clinical response.

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil) (NDC 45802-485-26) is supplied in bottles containing 4 fluid ounces and with 2 shower caps.

Storage: Keep tightly closed. Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see *USP Controlled Room Temperature*].

## **17 PATIENT COUNSELING INFORMATION**

### Administration Instructions

Advise patients that fluocinolone acetonide topical oil is for topical use only [see *Dosage and Administration (2)*].

Instruct patients not to apply fluocinolone acetonide topical oil to the diaper area as diapers or plastic pants may constitute occlusive use [see *Dosage and Administration (2)*].

Advise patients to avoid use of fluocinolone acetonide topical oil on the face, axillae, or groin unless directed by their healthcare provider [see *Dosage and Administration (2)*].

Advise patients to discontinue therapy when control of disease is achieved. Instruct patients to contact their healthcare provider if no improvement is seen within 2 weeks [see *Dosage and Administration (2)*].

### Endocrine System Adverse Reactions

Instruct patients not to use other corticosteroid-containing products while using fluocinolone acetonide topical oil without first consulting their healthcare provider [see *Warnings and Precautions (5.1)*].

### Ophthalmic Adverse Reactions

Advise patients to avoid contact with the eyes and in case of contact, wash eyes liberally with water. Instruct patients to tell their healthcare provider if they develop any visual symptoms [see *Warnings and Precautions (5.3)*].

### Pregnancy and Lactation

Advise women to use fluocinolone acetonide topical oil on the smallest area of skin and

for the shortest duration possible while pregnant or breastfeeding. Advise patients that are breastfeeding not to apply fluocinolone acetonide topical oil directly to the nipple and areola to avoid direct infant exposure [*see Use in Specific Populations (8.1 and 8.2)*].

Manufactured by Padagis®  
Yeruham, Israel

[www.padagis.com](http://www.padagis.com)

Rev 07-25  
4K526 RC F7

**PACKAGE/LABEL PRINCIPAL DISPLAY PANEL**

NDC 45802-485-26

Rx Only

Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil)

FOR TOPICAL USE ONLY

NOT FOR ORAL, OPHTHALMIC, OR INTRAVAGINAL USE

SHAKE WELL BEFORE USE

NET CONTENTS

118.28 mL (4 FL OZ)



The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.

S/N [insert product's serial number]  
 Lot [insert product's lot number]  
 Exp [insert product's expiration date]

**FLUCINOLONE ACETONIDE**

fluocinolone acetonide oil

## Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:45802-485
<b>Route of Administration</b>	TOPICAL		

## Active Ingredient/Active Moiety

<b>Ingredient Name</b>	<b>Basis of Strength</b>	<b>Strength</b>
<b>FLUOCINOLONE ACETONIDE</b> (UNII: 0CD5FD6S2M) (FLUOCINOLONE ACETONIDE - UNII:0CD5FD6S2M)	FLUOCINOLONE ACETONIDE	0.01 mg in 100 mL

## Inactive Ingredients

<b>Ingredient Name</b>	<b>Strength</b>
<b>ISOPROPYL ALCOHOL</b> (UNII: ND2M416302)	
<b>ISOPROPYL MYRISTATE</b> (UNII: 0RE8K4LNJS)	
<b>LIGHT MINERAL OIL</b> (UNII: N6K5787QVP)	
<b>OLETH-2</b> (UNII: 7L6R1SQ6M0)	

## Product Characteristics

<b>Color</b>	YELLOW (TO PALE YELLOW)	<b>Score</b>	
<b>Shape</b>		<b>Size</b>	
<b>Flavor</b>		<b>Imprint Code</b>	
<b>Contains</b>			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:45802-485-26	1 in 1 CARTON	06/14/2017	
1		118.28 mL in 1 BOTTLE; Type 0: Not a Combination Product		

## Marketing Information

<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
ANDA	ANDA202848	06/14/2017	

**Labeler** - Padagis Israel Pharmaceuticals Ltd (600093611)